- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00486772
Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD
Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients while the exact mechanism has not been clarified.
This study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-A concentrations and ED seen in CKD patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CKD stage 4 patients older than 18 years of age and willing to participate to the study were screened. Those who had serum phosphorus > 5.5 mg/dl were evaluated for the study. Patients with diabetes mellitus, history of coronary artery disease, smokers and those taking statins or renin-angiotensin blockers were excluded because of the effect of these factors on endothelial dysfunction. Of 62 screened patients 50 met the study criteria and were included in this study. Thirty-two healthy subjects were studied as controls. The ethical committee of Gulhane School of Medicine approved the study and written informed consent was obtained from all patients.
Study design:
This was a randomized study conducted from 2005 through 2006 in Gulhane School of Medicine. The Outpatient Clinic of Department of Nephrology is a tertiary referral center. At admission, most patients were untreated (including phosphate binders) or treated only with antihypertensive agents. After the first evaluation, patients receiving phosphate binders (n=9) underwent a 2-week washout period. Patients who developed a phosphate level >5.5 mg/dl during this period were included in the study. Patients were randomly assigned in 1:1 ratio to receive sevelamer (Renagel capsule) or calcium acetate (Phos Ex tablet). The treatment phase was 8 weeks. During the study period serum calcium and phosphorus concentration were measured every 2 weeks and the dose of phosphate binders were titrated to achieve a serum phosphorus concentration < 5.5 mg/dl. The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day and for calcium acetate (1000 mg) 1 tablet three times a day. The medications were given with meal and the doses were increased as needed. Patients were not given calcitriol during the study period.
Fasting blood samples were taken before and after the study to measure serum creatinine, serum albumin, hs-CRP, insulin, iPTH, lipid profile and serum fetuin-A concentration. Additionally, flow-mediated dilatation (FMD) was also evaluated before and after the study.
Study Type
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CKD stage 4 patients
- Older than 18 years of age
- Non-diabetic
- Serum phosphorus > 5.5 mg/dl
Exclusion Criteria:
- Diabetes mellitus
- History of coronary artery disease
- Smokers
- Taking statins or renin-angiotensin blockers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mahmut I Yilmaz, Gulhane School of Medicine
Publications and helpful links
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-Yilmaz
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Diseases
-
University Hospital, MontpellierTerminated
-
Terumo Europe N.V.CompletedPeripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular ProcedureBelgium, France, Germany
-
Alvotech Swiss AGActive, not recruitingChorioretinal Vascular DiseaseGeorgia
-
University of California, IrvineUniversity of Oklahoma; US Department of Veterans Affairs; C. R. Bard; Long Beach...CompletedPeripheral Vascular Disease | Cardiac Catheterization | Vascular Access ComplicationsUnited States
-
AmgenCompletedChorioretinal Vascular DiseaseUnited States
-
Duke UniversityTerminatedRetinal Vascular DiseaseUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Regeneron PharmaceuticalsCompletedChorioretinal Vascular DiseaseUnited States
-
Terumo Europe N.V.Terumo Medical CorporationRecruitingPeripheral Vascular Disease | Hemostasis | Vascular Closure | Femoral Artery | Endovascular ProcedureFrance, Germany, Netherlands
Clinical Trials on Sevelamer (Renagel), calcium acetate (Phos-ex)
-
Genzyme, a Sanofi CompanyCompletedPeritoneal Dialysis | Chronic Kidney DiseaseBelgium, United Kingdom, Denmark, France, Italy, Netherlands, Spain
-
Chugai Pharma TaiwanCompletedHemodialysis | Hyperphosphatemia | Cardiovascular Events
-
Nabi BiopharmaceuticalsCompletedArteriosclerosis | Hyperparathyroidism, Secondary | CalcinosisUnited States
-
Tel-Aviv Sourasky Medical CenterGenzyme, a Sanofi Company; Wolfson Medical CenterCompletedHemodialysis | End Stage Renal Disease | Intimal Media ThicknessIsrael
-
Azienda Sanitaria ASL Avellino 2CompletedCardiovascular MortalityItaly
-
Assiut UniversityUnknownHyperphosphatemia
-
Karolinska InstitutetGöteborg UniversityWithdrawnInsulin Resistance | Kidney Failure, Chronic | End-Stage Renal Disease | HyperphosphatemiaSweden
-
Fresenius Medical Care North AmericaCompletedChronic Kidney DiseaseUnited States
-
ArdelyxCompletedHyperphosphatemiaUnited States
-
Gulhane School of MedicineCompletedWe Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.Turkey